SEATTLE GENETICS INC/WA

Form 4 April 06, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB 3235-0287

Number:

Expires:

January 31, 2005

Estimated average burden hours per

response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

Common

Common

Common

Common

Stock

Stock

Stock

Stock

04/05/2017

04/05/2017

04/05/2017

04/05/2017

(Print or Type Responses)

1. Name and Address of Reporting Person * SIEGALL CLAY B	2. Issuer Name and Ticker or Trading Symbol SEATTLE GENETICS INC /WA [SGEN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) (Middle) 21823 30TH DRIVE SE	3. Date of Earliest Transaction (Month/Day/Year) 04/05/2017	X Director 10% OwnerX Officer (give title Other (specify below) President and CEO
(Street) BOTHELL, WA 98021	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - Non-Derivative Securities Ac	equired, Disposed of, or Beneficially Owned
(Instr. 3) any	tion Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) h/Day/Year) (Instr. 8) (A) or Code V Amount (D) Price	Beneficially Form: Direct Beneficial Owned (D) or Ownership Following Indirect (I) (Instr. 4) Reported (Instr. 4) Transaction(s) (Instr. 3 and 4)
Common 04/05/2017 Stock	M 10,423 A \$ 10.29	₉ 646,858 D

 $S^{(1)}$

M

 $S^{(1)}$

M

10,423 D

A

D

Α

715

715

3,327

(2)

\$

(4)

62.93

636,435 (3)

636,435 (3)

\$ 10.2 637,150

\$ 10.2 639,762

D

D

D

D

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

Common Stock $S_{\underline{(1)}}$ $S_{\underline{(3)}}$ $S_{\underline{(3)}}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right to buy)	\$ 10.2	04/05/2017		M	715	<u>(6)</u>	05/25/2017	Common Stock	71
Non-Qualified Stock Option (right to buy)	\$ 10.2	04/05/2017		M	3,327	<u>(6)</u>	05/25/2017	Common Stock	3,3
Non-Qualified Stock Option (right to buy)	\$ 10.29	04/05/2017		M	10,423	<u>(7)</u>	08/28/2017	Common Stock	10,4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
SIEGALL CLAY B 21823 30TH DRIVE SE	X		President and CEO			
BOTHELL, WA 98021						

Signatures

By: /s/ Jean Liu For: Clay B. 04/06/2017 Siegall

**Signature of Reporting Person Date

Reporting Owners 2

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
 - Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$62.98 to \$63.74. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange
- Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- (3) Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
 - Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$62.91 to \$62.98. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange
- (4) Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
 - Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$61.71 to \$62.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange
- Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- (6) Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares are fully vested on 5/25/11.
- (7) Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares are fully vested on 8/28/11.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.